NO20090312L - Quinolinonderivater og deres farmasoytiske sammensetninger - Google Patents

Quinolinonderivater og deres farmasoytiske sammensetninger

Info

Publication number
NO20090312L
NO20090312L NO20090312A NO20090312A NO20090312L NO 20090312 L NO20090312 L NO 20090312L NO 20090312 A NO20090312 A NO 20090312A NO 20090312 A NO20090312 A NO 20090312A NO 20090312 L NO20090312 L NO 20090312L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
quinolinone derivatives
compounds
quinolinone
derivatives
Prior art date
Application number
NO20090312A
Other languages
English (en)
Other versions
NO341709B1 (no
Inventor
Olivier Lohse
Jean-Louis Reber
Stephanie Monnier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090312L publication Critical patent/NO20090312L/no
Publication of NO341709B1 publication Critical patent/NO341709B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

i salt eller solvat form, hvor W, Rx, Ry, R1, R2, R3, R4, R5, R6 og R7 og A har betydningene som indkert i redegjørelsen, er nyttige for behandling av sykdommer mediert ved pVadrenoreseptoren. Farmasøytiske sammensetninger som inneholder forbindelsene og fremgangsmåtene for å fremstille forbindelsene er også beskrevet.
NO20090312A 2006-06-30 2009-01-20 Quinolinderivater, fremgangsmåte for fremstilling og deres farmasøytiske sammensetninger, samt anvendelse for behandling av inflammatorisk eller obstruktiv luftveissykdom. NO341709B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NO20090312L true NO20090312L (no) 2009-01-28
NO341709B1 NO341709B1 (no) 2018-01-02

Family

ID=38610531

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20090312A NO341709B1 (no) 2006-06-30 2009-01-20 Quinolinderivater, fremgangsmåte for fremstilling og deres farmasøytiske sammensetninger, samt anvendelse for behandling av inflammatorisk eller obstruktiv luftveissykdom.
NO2020041C NO2020041I1 (no) 2006-06-30 2020-11-23 Indakaterolacetat eller indakaterolxinafoat i kombinasjon med mometasonfuroat, fortrinnsvis indakaterolacetat i kombinasjon med mometasonfuroat
NO2020044C NO2020044I1 (no) 2006-06-30 2020-12-07 Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrronium

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2020041C NO2020041I1 (no) 2006-06-30 2020-11-23 Indakaterolacetat eller indakaterolxinafoat i kombinasjon med mometasonfuroat, fortrinnsvis indakaterolacetat i kombinasjon med mometasonfuroat
NO2020044C NO2020044I1 (no) 2006-06-30 2020-12-07 Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrronium

Country Status (27)

Country Link
US (2) US8198450B2 (no)
EP (1) EP2044025B1 (no)
JP (1) JP5253392B2 (no)
KR (1) KR101402398B1 (no)
CN (1) CN101479245B (no)
AU (1) AU2007264946B2 (no)
BR (1) BRPI0713951B8 (no)
CA (1) CA2654801C (no)
CY (3) CY1113733T1 (no)
DK (1) DK2044025T3 (no)
ES (1) ES2396987T3 (no)
FR (2) FR20C1054I1 (no)
HK (1) HK1127597A1 (no)
HR (1) HRP20121074T1 (no)
HU (2) HUS2000043I1 (no)
IL (1) IL195796A (no)
LT (2) LTC2044025I2 (no)
MA (1) MA30540B1 (no)
MX (1) MX2008016542A (no)
MY (1) MY150468A (no)
NO (3) NO341709B1 (no)
NZ (1) NZ573292A (no)
PL (1) PL2044025T3 (no)
PT (1) PT2044025E (no)
SI (1) SI2044025T1 (no)
WO (1) WO2008000839A1 (no)
ZA (1) ZA200809948B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
KR20120120453A (ko) 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20150374623A1 (en) 2013-03-14 2015-12-31 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
DE602004019198D1 (de) 2003-04-04 2009-03-12 Novartis Ag Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
AU2006227300B2 (en) 2005-03-21 2012-02-02 Eli Lilly And Company Imidazopyridazine compounds
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
US8198450B2 (en) 2012-06-12
KR101402398B1 (ko) 2014-06-03
JP5253392B2 (ja) 2013-07-31
CN101479245B (zh) 2013-05-22
KR20090023651A (ko) 2009-03-05
ES2396987T3 (es) 2013-03-01
AU2007264946A1 (en) 2008-01-03
MA30540B1 (fr) 2009-06-01
NO2020041I1 (no) 2020-11-23
CA2654801C (en) 2014-08-19
IL195796A (en) 2016-03-31
FR20C1063I1 (fr) 2021-01-22
BRPI0713951A2 (pt) 2012-12-04
IL195796A0 (en) 2009-09-01
PT2044025E (pt) 2012-12-17
LTC2044025I2 (lt) 2022-10-10
PL2044025T3 (pl) 2013-02-28
CY2020038I1 (el) 2021-03-12
HUS2000043I1 (hu) 2020-12-28
NO2020044I1 (no) 2020-12-07
CY1113733T1 (el) 2016-06-22
DK2044025T3 (da) 2013-01-14
AU2007264946B2 (en) 2011-01-20
MX2008016542A (es) 2009-01-19
CN101479245A (zh) 2009-07-08
CY2020038I2 (el) 2021-03-12
HUS2000053I1 (hu) 2020-12-28
NO341709B1 (no) 2018-01-02
CY2020041I1 (el) 2021-03-12
CY2020041I2 (el) 2021-03-12
CA2654801A1 (en) 2008-01-03
WO2008000839A1 (en) 2008-01-03
BRPI0713951B1 (pt) 2019-08-13
EP2044025A1 (en) 2009-04-08
FR20C1054I1 (fr) 2020-12-25
EP2044025B1 (en) 2012-10-03
JP2009541455A (ja) 2009-11-26
SI2044025T1 (sl) 2013-01-31
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
NZ573292A (en) 2011-03-31
ZA200809948B (en) 2009-05-25
LTPA2020535I1 (lt) 2020-12-28
US20090325912A1 (en) 2009-12-31
BRPI0713951B8 (pt) 2021-05-25
US20120316142A1 (en) 2012-12-13
MY150468A (en) 2014-01-30
LTPA2020538I1 (lt) 2021-01-11

Similar Documents

Publication Publication Date Title
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
TW200745066A (en) Novel PTP1B inhibitors
NO20090628L (no) Pyridizinon derivativater
SV2010003463A (es) Compuestos organicos
WO2009155121A3 (en) Inhibitors of pi3 kinase
TN2010000167A1 (en) Organic compounds
MX2014012695A (es) Derivados de isoindolona.
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
ME01515B (me) PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
TW200833675A (en) Nicotinamide derivatives
MX2010006421A (es) Compuestos organicos.
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
NO20055688L (no) Organiske forbindelser
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
NO20090312L (no) Quinolinonderivater og deres farmasoytiske sammensetninger
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
TW200643013A (en) Pyrazoles

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: INDAKATEROLACETAT ELLER INDAKATEROLXINAFOAT I KOMBINASJON MED MOMETASONFUROAT FORTRINNSVIS INDAKATEROLACETAT I KOMBINASJON MED MOMETASONFUROAT; REG. NO/DATE: EU/1/20/1439 20200608

Spc suppl protection certif: 2020041

Filing date: 20201123

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: INDAKATEROLACETAT ELLER INDAKATEROLXINAFOAT FORTRINNSVIS INDAKATEROLACETAT I KOMBINASJON MED MOMETASONFUROAT OG GLYKOPYRRONIUM; REG. NO/DATE: EU/1/20/1438 20200714

Spc suppl protection certif: 2020044

Filing date: 20201207